Fibronostics Secures Financing, Announces New CEO
Summary
NEW YORK and SINGAPORE, June 15, 2022 /PRNewswire/ -- Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. Its lead product, LIVERFASt, is a patented neural network driven AI technology combining anthropometrics with broadly available biomarkers from a single blood draw. LIVERFASt provides diagnostic and prognostic insights of clinical relevance, and the test is easy to conduct at large scale which is crucial in the identification of very prevalent conditions such as NAFLD/NASH in metabolic subjects. Recent guideline updates from EASL recognized biopsy drawbacks and acknowledged non-invasive methods can identify advanced fibrosis in patients better than by clinical acumen alone. It has begun commercializing globally and is currently preparing for FDA submission after successfully completing the data acquisition phase of its clinical trial.